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Abstract 
The outcome and quality of life of chronic
myeloid leukemia (CML) patients has remark-
ably changed with the treatment of tyrosine
kinase  inhibitors  (TKIs).  Currently,
hematopoietic  stem  cell  transplantation
(HSCT) is considered mainly as a third line
salvage therapy in cases of TKIs resistance or
intolerance. Here we describe a patient with
chronic phase CML who developed both resist-
ance and late occurrence of s severe thrombo-
cytopenia on first and second generation TKIs
and eventually underwent HSCT. Although the
mechanism  of  the  myelosuppression  is  not
fully understood, we showed for the first time
the  development  of  dose  dependent  platelet
antibodies in the presence of TKIs, suggesting
the possibility of TKIs induced thrombocytope-
nia.  Our  case  emphasizes  that  late  develop-
ment of severe myelosuppression during ima-
tinib treatment is probably an important indi-
cation for consideration of early HSCT. 
Introduction
Chronic myeloid leukemia (CML) accounts
for approximately 20% of all adult leukemia. It
is a clonal myeloproliferative disorder, which is
caused by the Philadelphia (Ph) chromosome
that  produces  the  constitutively  active  BCR-
ABL  tyrosine  kinase.  Tyrosine  kinase
inhibitors (TKIs) act by competitive inhibition
of adenosine triphosphate (ATP) that binds to
BCR-ABL.  This  process  prevents  the  down-
stream  signal  transduction  pathways.1,2
Imatinib is the first tyrosine kinase inhibitor
to have achieved long term disease control in
the majority of patients with CML.2 In an inter-
nationally randomized study of interferon ver-
sus  ST1571  (IRIS),  63%  of  all  imatinib
patients'  showed  a  complete  cytogenetic
response (CCyR) and the estimated event free
survival (EFS) was 83%.3 The degree of treat-
ment response at earlier time points in the
CML correlates with EFS and time to progres-
sion to accelerated phase/ blast crisis (AP/BC). 
However, imatinib use is complicated by the
development  of  resistance  or  intolerance,3-7
which leads to suboptimal responses or treat-
ment failure.2 Imatinib resistance appears to
be multifactorial.8,9 The most common mecha-
nisms for the development of this resistance
are the occurrence of a mutation in the BCR-
ABL tyrosine kinase domain that inhibits ima-
tinibs ability to bind to ABL and poor patient
compliance.9,10
Most  side  effects  of  imatinib  are  mild  to
moderate and are often self limiting. Grade ≥3
neutropenia  and  thrombocytopenia  were
reported in 17% and 9% of the patients respec-
tively, and most of them occurred within the
first  two  years  of  imatinib  treatment.7
Furthermore, most myelosuppression is dose-
dependent, reversible, and can be managed by
dose  interruption  or  reduction.  In  the  IRIS
study, 4% of the imatinib group discontinued
therapy owing to an adverse event.
The second generation TKIs - nilotinib or
dasatinib - are more potent than imatinib and
can  overcome  most  imatinib  resistant  BCR-
ABL mutations.2 In a two year follow up of a
phase 2 study, nilotinib was given to patients
with chronic phase (CP) or advanced phase
CML who had failed, or were unable to tolerate,
initial imatinib therapy.Cross-intolerance with
imatinib (defined as occurrence of a grade ≥3
adverse event (AE) or persistence or recurrent
grade 2 of the same AE that previously led to
discontinuation of imatinib) was observed in a
sub-analysis of 121 out of 459 patients with CP
and AP. All of the seven patients who discontin-
ued nilotinib did so due to thrombocytopenia.11
Additional data suggests that patients who
develop  severe  hematological  toxicity  with
imatinib treatment, are at high risk of having
a suboptimal response or hematological cross-
intolerance with a second generation TKI.12
Currently, the general assumption is that an
initial trial of second-generation TKIs, before
proceeding to hematopoietic stem cell trans-
plantation (HSCT), is reasonable in nearly all
patients in whom imatinib treatment fails, par-
ticularly, because HSCT is available only to a
minority of patients and is associated with sig-
nificant morbidity and mortality.13
The Hammersmith score helps predict the
response  to  second  generation  TKI's  and  is
based on calculating the cytogenetic response
to imatinib, the Sokal high risk group and the
recurrence of neutropenia.14 It is still unclear
whether a small, select group of young CML
patients  in  CP  who  fail  imatinib  treatment
should  undergo  allogeneic  HSCT  without
being first treated with second-line TKIs. 
Here  we  present  a  CP  CML  patient  who
developed  severe  thrombocytopenia  during
treatment with all three TKI's and we raise the
question as to whether an early HSCT should
have been performed.
Case Report
A 34-year-old man was diagnosed with Ph-
positive CML in May 2009, after presenting the
preceding year with weight loss and a white
blood  cell  count  (WBC)  of  188ﾥ109/L.  The
patient received hydroxyurea for three weeks
followed  by  imatinib  400  mg/day.  Within  a
month he achieved a complete hematological
response (CHR).
The  patient  entered  a  clinical  study  that
assessed therapeutic levels of imatinib and he
was found to have a sub-therapeutic level of
640 ng (the study estimated an optimal thera-
peutic level of approximately 1000 ng).15 After
three months of imatinib treatment the BCR-
ABL transcript level decreased by only 0.2 logs
as compared to the test performed at diagno-
sis. In November 2009, the patient complained
of  flu  like symptoms  and  developed  severe
thrombocytopenia with a platelet (PLT) count
of 22ﾥ109/L, WBC of 4.4ﾥ109/L with absolute
neutrophil count of 0.8ﾥ109/L, and hemoglobin
of 12.8g/dL. A peripheral blood smear showed
atypical  lymphocytes  with  toxic  granulation,
suggestive of acute viral infection. The follow-
ing tests were normal or negative; herpes sim-
plex  virus,  herpes  zoster,  cytomegalovirus,
epstein barr virus, IgM antibodies, hepatitis B
surface antigen (HBsAg), hepatitis B surface
antibody (HBsAb), hepatitis c virus antibody ,
antinuclear antibody and human immunodefi-
ciency virus antibody. Bone marrow (BM) aspi-
ration and biopsy revealed a hypoplastic mar-
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row  with  a  decreased  number  of  megakary-
ocytes, no blast cells and no excess of reticulin.
Cytogenetic studies demonstrated 93% mitotic
cells with Ph chromosome and fluorescent in
situ hybridization (FISH) showed 83% of the
cells with BCR-ABL. Mutation analysis did not
reveal a mutation in the BCR-ABL. The treat-
ment with imatinib was stopped for two weeks
and Nilotinib 400 mg twice daily was started
after the platelets rose above 50,000 µL. Within
another two weeks, there was a decline in his
blood count with PLT 15ﾥ109/L, normal levels of
WBC (5.6ﾥ109/L), ANC of 1ﾥ109/L and hemo-
globin of 12.1g/dL. Of note, severe thrombocy-
topenia was also observed with a lower dose of
Nilotinib (200 mg twice daily). The treatment
with  nilotinib  was  discontinued  and  the
patient  was  treated  empirically  with  pred-
nisolone 80 mg daily. Within 2 weeks, the PLT
level increased to 110,000 µL. After the treat-
ment failure with nilotinib, dasatinib100 mg
once daily was started, with a similar decrease
in PLT level to 21ﾥ109/L. At this point, studies
to  evaluate  the  possibility  of  drug  (TKI's)
induced thrombocytopenia were performed.
Tests  for  anti-human  antibodies  IgM,  IgG
and IgA against PLTs were negative. However,
after  adding  the  TKI  drugs,  drug-dependent
antibodies against PLT were found using an
immunofluorescence test applying flow cytom-
etry  (Figure  1).  Moreover,  the  presence  of
these antibodies was dose dependent and was
thus  raised  the  possibility  of  drug  induced
thrombocytopenia. 
In August 2010, the status of his disease was
again  re-evaluated.  Cytogenetic  studies
showed 100% mitosis with Philadelphia chro-
mosome along with only one log reduction in
BCR-ABL  load.  Bone  marrow  aspiration  and
the peripheral counts revealed no blasts there-
by implying that the patient was still in the CP
of disease. Since the patient was intolerant to
all TKI's, therapy with interferon alpha 3MU
three times weekly was started before proceed-
ing  to  HSCT.  During  the  interferon  therapy,
there  was  a  minor  decrease  in  PLT  to
126ﾥ109/L. 
In September 2010 the patient underwent
an  uneventful,  allogeneic,  peripheral  blood
stem cell transplantation from a fully matched
unrelated male donor after conditioning with
BU-CY  (busulfan-  cyclophosphamide)  and
standard GVHD prophylaxis. Engraftment was
documented on day 13. RT-qPCR for BCR/ABL
transcripts performed on day 28 showed 6 log
decrease. A repeated test on day 72 showed an
increase  of  BCR-ABL/ABL  ratio  to  10–4 and
cyclosporine was discontinued. During the fol-
lowing month the patient presented with skin
rash,  diarrhea  and  elevated  liver  enzymes,
compatible with acute GVHD. There was a con-
comitant  decrease  of  BCR-ABL/ABL  to  10–6,
46XY karyotype and 100% donor chimerism. 
Today  the  patient  receives  corticosteroids
and tacrolimus for chronic limited GVHD. His
blood  count  is  normal,  with  complete  donor
chimerism and undetectable BCR/ABL.
Discussion
Our CML patient presented with an interest-
ing combination of resistance and intolerance
to TKIs that was manifested mainly as grade 3
thrombocytopenia.  Interruption  of  therapy,
dose reduction and therapy with second gener-
ation TKIs, did not prevent the recurrence of
the adverse hematological events. Mutations
in the BCR-ABL tyrosine kinase domain were
not found in our patient and he was compliant
with medication.
In CML, the hematopoiesis is mainly derived
from the Ph+ stem cells and myelosuppression
is usually observed within the first weeks of
TKI treatment. The latter is probably due to
delayed recovery of the normal Ph–stem cells.
The reduced reserve of residual, healthy Ph -
bone marrow (BM) is incapable of reconstitut-
ing the peripheral blood count.16,17 In the case
of  our  patient,  the  cytopenia  occurred  six
months after the initiation of imatinib therapy
and  the  Ph+ clone  was  not  suppressed,  as
shown by the 100% Ph+ mitotic cells in the
karyotype analysis.    
The demonstration of anti-platelets antibod-
ies in the patients' serum only in the presence
of TKIs implies that the possible mechanism is
indeed drug (TKIs) induced thrombocytopenia.
However, the full significance of this finding is
unclear  since,  unlike  in  ITP  (Immune
Thrombocytopenic  Purpura),  there  were
decreased numbers of megakaryocytes in the
BM, and since no TKI induced immune throm-
bocytopenia has been previously reported.
HSCT is effective therapy for patients with
CP-CML but in the current era of second gen-
eration TKI's it is mainly indicated for patients
who  develop  resistance.  Less  than  5%  of
patients  develop  repeated  severe  myelosup-
pression after only a few months of TKI thera-
py. Late development of severe myelosuppres-
sion during imatinib treatment is probably an
important indication for consideration of early
HSCT. Future studies are needed in order to
understand  the  pathogenesis  of  recurrent
severe myelosuppression during TKI therapy. 
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